NUTRITIONAL APPROACH FOR INHIBITING BONE RESORPTION IN INSTITUTIONALIZED ELDERLY WOMEN WITH VITAMIN D INSUFFICIENCY AND HIGH PREVALENCE OF FRACTURE

J.-P. BONJOUR[1], V. BENOIT[2], O. POURCHAIRE[3], B. ROUSSEAU[2], J.-C. SOUBERBIELLE[4]

University Hospitals and Faculty of Medicine, Geneva, Switzerland. 1. Division of Bone Diseases, WHO Collaborating Center for Osteoporosis Prevention; 2. Groupe de Recherche Nutritionnelle, Yoplait, 150 rue Gallieni, 92641 Boulogne, France; 3. Hôpital Local Intercommunal de Morestel, 539 rue François Perrin, 38510 Morestel, France; 4. Laboratoire d'Explorations Fonctionnelles, Hôpital Necker-Enfant Malades, Paris, France. Corresponding author: Professor Jean-Philippe Bonjour, MD, Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Rue Micheli-du-Crest 24, CH – 1211 Geneva 14, Switzerland, Phone: +4122 372 99 50, Fax: +4122 382 99 73, Email: jean-philippe.bonjour@unige.ch

Abstract: *Background:* Nutritional approach to the deterioration of bone integrity and increased fracture risk appears to be particularly appropriate in elderly women living in nursing homes. *Objective:* To investigate the beneficial effect of the consumption of soft plain cheese on bone resorption markers in institutionalized elderly women. *Design:* Prospective, randomized crossover controlled study. *Setting:* Six French nursing homes or other institutions for elderly. *Participants:* Institutionalized women $\geq$ 65 years old with low vitamin D status and calcium intake below 700 mg/day. *Intervention:* Consumption of soft plain cheese made of semi-skimmed milk which was fortified by both vitamin D3 (+1.25μg/100g) and milk extracted Ca, thus achieving a total Ca content of 151 mg/100g as compared to about 118 mg/100g for standard fresh cheese. Two servings were taken every day during the 6 weeks that preceded or followed a period of 6 weeks without soft plain cheese consumption. *Measurements:* The primary end point was the change in serum carboxy terminal cross-linked telopeptide of type I collagen (CTX) selected as a marker of bone resorption. *Results:* 29 women aged 73-94 yr were selected, 21 of them with mean age 87.2±6.1 years remained compliant. The intervention increased calcium and protein intakes by 51% (904±228 vs. 599±122 mg/d) and 33 % (74.2±17.1 vs. 55.6±12.7 g/d, mean±SD), respectively. The dietary intervention was associated with a statistically significant increase in serum levels of both 25OHD and IGF-I, while those of PTH, CTX and TRAP5b were significantly reduced. Compliance was 93,4 %. The daily consumption of two servings of soft plain cheese was well accepted in terms of tastiness and appetite suited portion size. *Conclusion:* This randomized crossover controlled trial demonstrates that in elderly women living in nursing homes, the consumption of soft plain cheese increasing the supply of vitamin D, calcium and proteins, could reduce bone resorption and thereby reduce the risk of incidental fragility fractures in the long term.

Key words: Elderly women, osteoporosis prevention, nutritional intervention, fortified cheese, bone resorption.

Introduction

Fragility fractures in elderly can be the long term consequence of an increase in bone remodeling, leading to bone loss with micro structural alterations of both cortical and trabecular structures (1, 2). In the primary prevention of osteoporosis, adequate nutrition and physical activity are important determinants of bone health throughout life. In the secondary prevention, several pharmaceutical agents have been shown to substantially reduce the risk of incident fragility fractures in postmenopausal women and in elderly (3-6). Secondary prevention of osteoporosis, however, cannot merely be limited to drug prescription. The adequate response to pharmaceutical treatment for preventing both further deterioration of bone structure and reducing the risk of falling is dependent upon other accompanying measures, among which nutrition is an essential contributor (7). Vitamin D, whenever cutaneous sources do not meet the needs, calcium and proteins are three nutrients influencing key processes in the acquisition and maintenance of bone structure. Several reviews on vitamin D, calcium (8-14) and proteins intakes (15-21) have underscored the importance of these three nutrients in the prevention of bone loss and, thereby in reducing the risk of fragility fracture in elderly.

Dairy products, by providing both calcium and proteins, can be expected to play a positive role on bone health. Milk consumption has been shown to favorably affect bone remodeling in postmenopausal women (22, 23) and in elderly (24). In an open study carried out in institutionalized vitamin D deficient women, we observed an apparent beneficial effect on bone turnover markers after 4 weeks of soft plain cheese consumption, providing about 17-25 % of the recommended daily intakes of vitamin D, calcium and proteins (25).

In the present report, we investigated, in another cohort of institutionalized elderly women, and using a crossover controlled study design whether the same intervention could significantly reduce bone resorption markers. In order to optimally capture any change in bone resorption rate, two circulating markers of this process were monitored atthe end of two sequential 6-week periods, with and without soft plain cheese consumption. One biochemical marker (CTX) was selected for its capacity to reflect more change in osteoclast function, whereas the other (TRAP 5b) would preferentially capture modification in the number of osteoclast (26). As designed the present study could also adequately assess how well the tested food was tolerated.

Methods

Participants and Design

The study involved six French nursing homes or institutions for elderly. All of them were selected because they provided both medical supervision and adequate food consumption monitoring. The screening of the subjects for eligibility started on January 28 2008, after the study protocol had been approved by both the regional (Lyon) and national ("Direction Générale de la Santé) ethical committees.

Inclusion/exclusion criteria were as follow: women ≥ 65 years old living in nursing or elderly people home (Etablissement d'Hébergement pour Personnes Agées Dépendantes) having given their informed consent; calcium intake lower than 700 mg daily as assessed by frequency questionnaire (27); daily sun exposure of uncovered arms limited to less than 20 minutes; serum level of 25-hydroxyvitamin D (25OHD) ≥ 4 ng/ml in order to avoid enrolling subjects with severe vitamin D deficiency requiring appropriate medical management; serum PTH ≥ 46 ng/l and ≤ 150 ng/l; creatinine clearance, as calculated according to Cockroft formula, either normal or moderately reduced with value ≥ 30ml/min; appreciating to eat dairy foods; Mini Nutritional Assessment (MNA) with score ≥ 21 (28); no consumption during the last 6 months of food enriched withvitamin D and/or calcium; no treatment for osteoporosis or other bone diseases, including the following pharmaceutical agents: calcitonin, bisphosphonates, raloxifene, teriparatide, strontium ranelate; no disease with poor prognosis at short term; no participation in a clinical trial during the last 3 months preceding the entry into the study; no osteoporotic fracture during the 12 months preceding the study; not confined to bed or taking meals in her private room.

According to these inclusion/exclusion criteria 29, out of the 40 screened subjects were eventually enrolled into the study. Subjects were selected from the results recorded at a first visit that took place about 3 weeks before the beginning of the trial. The intervention consisted in the consumption of soft plain cheese made of semi-skimmed milk which was enriched by both vitamin D (+1.25 μg/100g) and milk calcium, thus achieving a total calcium content of 151 mg/100g, as compared to about 118 mg /100g for standard fresh cheese according to the French CIQUAL food database. Two servings of 100g each were taken every day during 6 weeks. They provided daily: 164 Kcal; 2.5 μg vitamin D; 302 mg calcium; 233 mg phosphorus 14.2 g proteins. Subjects were randomly assigned to consume the tested dairy product during the first or the second 6-week period. During the 12-week intervention phase, two blood samples were collected, i.e. by the end of the 6-week periods with and without soft plain cheese consumption.

The main endpoints were the differences in two serum markers of bone resorption, carboxy terminal cross-linked telopeptide of type I collagen (CTX) and tartrate resistant acid phosphatase, isoform 5b (TRAP 5b) between the end of the period with and without soft plain cheese consumption.

Biochemical measurements

Calcium was measured by colorimetry, sodium and potassium by indirect potentiometry with the use of specific electrodes, and creatinine by the Jaffe reaction (Roche Diagnostics, Meylan, France). Serum parathyroid hormone (PTH), osteocalcin, amino-terminal propeptide of type I procollagen (PINP), and carboxy terminal cross-linked telopeptide of type I collagen (CTX, Cross-laps) were measured by automated immunochemiluminescence on the Elecsys platform (Roche Diagnostics, Meylan, France), as previously described (29). For these 4-biochemical analyses, the within- and between-run coefficient of variations (CV) were lower than 5%, whatever the concentration tested. The reference range of these assays was established in a group of 59 premenopausal healthy women aged 35-48 years. All of them had regular menses associated with plasma FSH concentration below 12 mU/l. They received a single dose of 100'000 IU of vitamin D3 one week before the blood sampling. The reference ranges were 10-46 pg/ml, 13-32 ng/ml, 19-50 ng/ml, and 700-3000 pmol/L for PTH, osteocalcin, P1NP, and C-TX, respectively. Bone alkaline phosphatase (BAP) was measured by automated immunochemiluminescence on the Access II platform (Beckman-Coulter, Chaska, Minesota, USA). BAP within-run CV was 6.7 % at mean concentration of 13.2 μg/l and below 5% at concentration above 25 μg/l. The reference range established in healthy premenopausal women was 4-15 μg/l.

Tartrate resistant acid phosphatase, isoform 5b (TRAP 5b), a surrogate marker of osteoclast number (26), was determined by immunoassay using a monoclonal antibody raised against TRAP 5b purified from human osteoclasts, and recombinant human TRAP as a reference standard (Bone TRAP® Enzyme Assay kit, SBA Sciences). Intra and inter assay coefficient of variation are lower than 4.8 and 5.2 %, respectively.

The serum level of 25-hydroxyvitamin D (25OHD) was measured by RIA (DiaSorin, Stillwater, Minesota, USA) as previously reported (30). Vitamin D insufficiency was defined as a serum level of 25OHD lower than 30 ng/ml (42). Serum IGF-I was measured by an immunoradiometric assay (IGF-I RIA-CT, Schering-Cis Bio, Gif sur Yvette, France) based on the use of two monoclonal antibodies directed toward different IGF I epitopes. In this method, bound IGF I is displaced from IGFBPs by acidification. A large excess of IGF-II is then added to the acid-treated serum to prevent reassociation of IGF-I with its carrier proteins when buffer is added. The analytical properties of this assay was recently reported (29). The normal range of serum IGF-I in women aged 36-85 years was 68-247 ng/ml.

Statistical analysis

The statistical power was estimated from the expected change in serum CTX that was a priori considered as the main endpoint of the study. By using a crossover design, it was expected that a difference would be detected in serum CTX between periods with and without soft plain cheese consumption by 20% with a power of 80% and a two-sided of

0.05. Twenty-nine subjects were eventually enrolled in order to secure a greater power to the study. Taking into account a measured intra-individual coefficient of variation (CV) of 10%, 15 % difference in serum CTX required a sample of 20 subjects in a crossover-designed -study.

The results are expressed as mean ± standard deviation (SD). Paired Student's t test was usedto assess differences between the values measured by the end of the two 6-week periods with and without soft plain cheese consumption, except osteocalcin for which a Wilcoxon rank-sum test was applied because of the skewed distribution of this variable. P values ≤ 0.05 were considered as statistically significant. Statistical analysis was made using the software SAS, version 8.02.

Results

The baseline demographic and biochemical characteristics, as assessed at the inclusion visit, are described in Tables 1 and 2.

Table 1

Baseline demographic characteristics of the 29 enrolled women, as assessed at the inclusion visit

Age (years)	86.9 ± 6.3
Age at menopause (years)	48.7 ± 4.2
Standing height (cm)	154 ± 8
Body weight (kg)	68.5 ± 15.6
BMI (kg/m²)	29.0 ± 6.4
Calcium intake (mg/d)	604 ± 132
Protein intake (g/d)	61.5 ± 12.3
MNA	25.8 ± 2.2

All values are means ± SD; BMI: Body Mass Index. ; MNA: Minimum Nutritional Assessment.

Out of the twenty-nine included subjects who fulfilled enrollment criteria, three women withdrew before the onset of the trial. In three others, blood was not collected in the fasting state, whereas for two women the dairy product was not taken during more than 4 days out of the 6 weeks defined in the study design. Therefore, the influence of the intervention was analyzed in 21 out of the 29 subjects initially enrolled at the inclusion visit. The anthropometric, nutritional and biochemical mean values of those 21 women kept in the analysis were not statistically different (data not shown) from the 29 selected subjects presented in Table 1 and 2.

Overall, 44.8 % of the enrolled women had already experienced at least one fracture with skeletal sites including wrist or forearm, spine and hip.

As compared to the reference ranges of serum biochemical analytes, mean albumin, and 25(OHD) values of the 29 enrolled subjects were low, whereas that of PTH was elevated (Table 2). To this high serum level of PTH was associated an increase in the bone markers, CTX and P1NP above the reference range established in premenopausal women, as assessed in the investigator laboratory (29). The intervention

increased calcium and protein intakes by 51% (904±228 vs. 599±122 mg/d) and 33 % (74.2±17.1 vs. 55.6±12.7 g/d, mean±SD), respectively.

Table 2

Serum biochemical characteristics in the 29 enrolled women as assessed at the inclusion visit

		Reference Values
Calcium (mmol/L)	2.24 ± 0.07	2.20 - 2.60
Inorganic Phosphate (mmol/L)	1.12 ± 0.12	0.85 -1.40
Albumin (g/L)	31.8 ± 2.7	35 - 50
Prealbumin (g/L)	0.23 ± 0.037	0.10 - 0.40
Creatinine (μmol/L)	83.9 ± 25.9	44 - 80
TSH (mUI/L)	2.2 ± 1.4	0.4 - 4.4
25OHD (ng/mL)	8.8 ± 7.5	30 - 80
PTH (ng/L)	75.8 ± 24.2	10 - 46*
CTX (pmol/L)	4325 ± 1948	700 – 3000 *
TRAP 5b (ng/mL)	5.75 ± 1.50	2.40 - 6.85 #
Osteocalcin (ng/mL)	30.3 ± 13.0	13 - 32*
BAP (μg/mL)	13.6 ± 5.3	4 - 15*
P1NP (ng/mL)	79.9 ± 31.8	19 - 50*
IGF-I (ng/mL)	111.6 ± 32.4	68-247

TSH: Thyroid-stimulating hormone; 25OHD: 25-hydroxyvitamin D; PTH: Parathyroid hormone; CTX: Carboxy terminal crosslinked telopeptide of type I collagen; TRAP 5b: Tartrate resistant acid phosphatase, isoform 5b; BAP: Bone Alkaline Phosphatase; P1NP : Amino-terminal propeptide of type I procollagen; IGF-I: Insulin-Like Growth Factor-I; * Reference range established in healthy premenopausal women aged 35-48 years; # Reference range established in healthy premenopausal women aged 22-54 years.

The dietary intervention produced a statistically significant increase in serum levels of both 25OHD and IGF-I, while those of PTH, CTX and TRAP5b were significantly reduced (Figure 1). No significant differences were recorded between the intervention and the control period for serum calcium, phosphate, albumin, prealbumin, BAP and P1NP (data not shown). Serum creatinine, which was slightly above the reference range corresponding to a clearance moderately reduced, but ≥30 ml/min using Cokroft formula. It was not modified by the intervention. MNA scores were not significantly different by the end of the 6-week period with (26.1±2.3) and without (26.3±1.9, mean±SD) soft plain cheese consumption.

The median number of soft plain cheese servings consumed during the 6 intervention weeks was 84.0 (ITT population n=29). The median of consumption duration was 44.0 days (ITT population n=29). The corresponding compliance was 94.8 %. The soft plain cheese acceptability, as evaluated by the end of the 6 weeks consumption was satisfactory with median score on a scale from 0 to 10 (best) for the following criteria: a) tastiness (8.0), b) portion size suited to subjects' appetite (8.5), c) absence of progressing tiredness during the food testing period (8.0).

Discussion

Elderly residents of age care facilities are at risk of suffering from inadequacies of nutrients such as vitamin D, calcium and

Figure 1

Serum biochemical variables after 6 weeks without (empty circles) and with (hatched circles) soft white cheese consumption in 21 institutionalized women. Vertical bars are SEM. *P*: statistical significance of the differences analyzed by paired t test. The decrease in the two biochemical markers of bone resorption, CTX and TRAP 5b reflecting osteoclast function and number were inhibited by 6.8% and 6% respectively, while osteocalcin was not decreased. See text for further details

proteins. In institutionalized elderly, insufficient supply of these three nutrients, in addition to the lack of sun exposure as far as vitamin D is concerned, amplifies the risk of fractures by increasing both bone loss rate and fall propensity (31-35). Hip fracture incidence is particularly elevated in nursing home residents, as observed in several countries (36-38). We recently reported results of an open trial exploring whether consumption of vitamin D and calcium enriched soft plain cheese may modify bone turnover in a way expected to attenuate the rate of bone loss among institutionalized elderly women (25). The results of this exploratory study suggested that fortified soft plain cheese consumed during one month by elderly women with vitamin D insufficiency can reduce bone resorption markers, namely CTX and TRAP 5b, by positively influencing Ca and protein economy, as expressed by decreased PTH and increased IGF-I, respectively (25). The foregoing randomized cross-over controlled study confirms that dietary intervention with the same fortified soft plain cheese during 6 weeks

significantly reduced bone resorption, as expressed by the significant decrease of both specific biochemical markers, CTX and TRAP 5b. As in the initial open study (25), these changes in bone resorption markers were associated with significant increase in serum levels of both 25OHD and IGF-I. Nevertheless, the decrease in serum PTH level was attenuated as compared to the former open trial. Of note, the new study indicated the quite satisfactory adherence and tolerance by this elderly women population of the soft plain cheese consumption, as previously recorded in the open trial (25).

In the former study, 43.2% (16 out of 37) of the enrolled subjects with mean age (±SD) 84.8±8.1 years reported to have experienced a fracture from the onset of menopause. In the present study, the prevalence of fractures was quite similar 44.8% (13 out of 29). Both age and prior fracture are recognized as two main clinical factors for the prediction of fragility fracture risk (39). This underscores the high risk of further fracture occurrence in institutionalized elderly women,

out of which more than 40% have already experienced at least one fracture.

In bone-related diseases, particularly osteoporosis, changes in clinical endpoints, such as bone mineral density and fragility fractures, require months to years, respectively, to manifest. Therefore, bone biochemical markers are extremely useful to predict the long-term responsiveness to treatment after a few weeks. Early changes in bone biochemical markers, particularly those reflecting bone resorption, such as CTX, predict the long-term rate of bone loss as well as the risk of incident fracture (40-49). The magnitude of the reduction in markers of bone resorption observed in the foregoing study is less than that observed following therapeutic doses of strong inhibitors of bone resorption such as bisphosphonates (44, 46, 47). But reduction of lower magnitude was also observed with weaker inhibitors of bone resorption, such as raloxifen (50), low doses of estrogen (51) strontium ranelate (52) and calcium with vitamin D supplementation (53). These compounds have been shown to exert positive effects on bone health in elderly, including reduction in vertebral fracture of similar magnitude to that obtained with most powerful bisphosphonates.

Much attention is now paid to scientific support for claims on foods as they are related to the effects of dietary components on body functions (54), including on bone health (55). In calcium and vitamin D enriched foods, a reduction in biochemical markers of bone resorption such as CTX and TRAP5b in the present study, mimics the effect of pharmaceutical supplementation combining this active agents(53). The concomitant stimulation of IGF-I, after six weeks of soft plain cheese consumption is similar to the early rise recently reported with selective supplementation of milk protein provided to elderly patients (56). Dietary proteins play a key role in the production of IGF-I (15). This physiological relation indicates that the function of proteins as supplied from diet should not be considered as merely that of "brick supplier" to the osteogenic cells, thus conferring on them the capacity to lay down the organic bone matrix. Amino acids from dietary proteins stimulate the hepatic production of IGF-I and, consequently, increase the circulating level of this growth factor that exerts anabolic action on both bone forming and skeletal muscle cells. The dietary protein-IGF-I system also positively influences the calcium-phosphate economy, thus favouring bone anabolism (18). Furthermore, some amino acids can directly stimulate IGF-I production by osteoblastic cells (57) or its expression in skeletal muscle cells (58). These systemic and local actions of both IGF-I and amino acids underscore the importance of adequate protein intake for preventing bone loss and sarcopenia and thus, for reducing the risk of fragility fractures in elderly (21).

Taken together, the biochemical changes observed in the present study are compatible with the combined influence of calcium, vitamin D and proteins, three nutrients contained in the tested dairy product in an amount providing 17-25 % of the daily recommended allowance for the elderly (59).

In conclusion, this randomized cross-over controlled study confirms a previous open trial by showing that, in elderly, regular consumption of a dairy food supplying three nutrients deemed to be essential for bone health exert a positive influence on biochemical markers of bone metabolism.

References

1. Melton LJ, 3rd, Khosla S, Atkinson EJ, O'Fallon WM & Riggs BL (1997) Relationship of bone turnover to bone density and fractures. J Bone Miner Res 12, 1083-1091.
2. Seeman E (2002) Pathogenesis of bone fragility in women and men. Lancet 359, 1841-1850.
3. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359, 2018-2026.
4. Seeman E & Eisman JA (2004) Treatment of osteoporosis: why, whom, when and how to treat. The single most important consideration is the individual's absolute risk of fracture. Med J Aust 180, 298-303.
5. Rizzoli. R & Kraenzlin M (2007) Approaches to optimizing bone health. In The living skeleton [Roux. C, editor]. Paris, France: Wolters Kluwer Health.
6. Parikh S, Avorn J & Solomon DH (2009) Pharmacological management of osteoporosis in nursing home populations: a systematic review. J Am Geriatr Soc 57, 327-334.
7. Bonjour JP, Schurch MA & Rizzoli R (1996) Nutritional aspects of hip fractures. Bone 18, 139S-144S.
8. Boonen S, Bischoff-Ferrari HA, Cooper C, Lips P, Ljunggren O, Meunier PJ & Reginster JY (2006) Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int 78, 257-270.
9. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D & Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92, 1415-1423.
10. Tang BM, Eslick GD, Nowson C, Smith C & Bensoussan A (2007) Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657-666.
11. Dawson-Hughes B & Bischoff-Ferrari HA (2007) Therapy of osteoporosis with calcium and vitamin D. J Bone Miner Res 22 Suppl 2, V59-63.
12. Broe KE, Chen TC, Weinberg J, Bischoff-Ferrari HA, Holick MF & Kiel DP (2007) A higher dose of vitamin d reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatr Soc 55, 234-239.
13. Bischoff-Ferrari HA & Staehelin HB (2008) Importance of vitamin d and calcium at older age. Int J Vitam Nutr Res 78, 286-292.
14. Bonjour JP, Gueguen L, Palacios C, Shearer MJ & Weaver CM (2009) Minerals and vitamins in bone health: the potential value of dietary enhancement. Br J Nutr 101, 1581-1596.
15. Bonjour JP, Schurch MA, Chevalley T, Ammann P & Rizzoli R (1997) Protein intake, IGF-1 and osteoporosis. Osteoporos Int 7 Suppl 3, S36-42.
16. Heaney RP (2001) Protein intake and bone health: the influence of belief systems on the conduct of nutritional science. Am J Clin Nutr 73, 5-6.
17. Bell J & Whiting SJ (2002) Elderly women need dietary protein to maintain bone mass. Nutr Rev 60, 337-341.
18. Bonjour JP (2005) Dietary protein: an essential nutrient for bone health. J Am Coll Nutr 24, 526S-536S.
19. Heaney RP & Layman DK (2008) Amount and type of protein influences bone health. Am J Clin Nutr 87, 1567S-1570S.
20. Morgan KT (2008) Nutritional determinants of bone health. J Nutr Elder 27, 3-27.
21. Gaffney-Stomberg E, Insogna KL, Rodriguez NR & Kerstetter JE (2009) Increasing dietary protein requirements in elderly people for optimal muscle and bone health. J Am Geriatr Soc 57, 1073-1079.
22. Palacios S, Castelo-Branco C, Cifuentes I, von Helde S, Baro L, Tapia-Ruano C, Menendez C & Rueda C (2005) Changes in bone turnover markers after calcium-enriched milk supplementation in healthy postmenopausal women: a randomized, double-blind, prospective clinical trial. Menopause 12, 63-68.
23. Bonjour JP, Brandolini-Bunlon M, Boirie Y, Morel-Laporte F, Braesco V, Bertiere MC & Souberbielle JC (2008) Inhibition of bone turnover by milk intake in postmenopausal women. Br J Nutr 100, 866-874.
24. Heaney RP, McCarron DA, Dawson-Hughes B, Oparil S, Berga SL, Stern JS, Barr SI & Rosen CJ (1999) Dietary changes favorably affect bone remodeling in older adults.

JNHA: GERIATRIC SCIENCE

J Am Diet Assoc 99, 1228-1233.

25. Bonjour JP, Benoit V, Pourchaire O, Ferry M, Rousseau B & Souberbielle JC (2009) Inhibition of markers of bone resorption by consumption of vitamin D and calcium-fortified soft plain cheese by institutionalised elderly women. Br J Nutr 102, 962-966

26. Henriksen K, Tanko LB, Qvist P, Delmas PD, Christiansen C & Karsdal MA (2007) Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int 18, 681-685.

27. Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C, Bellony R & Dubreuil A (1991) Evaluation of the calcium content of diet by frequential self-questionnaire. Rev Rhum Mal Osteoartic 58, 99-103.

28. Guigoz Y, Lauque S & Vellas BJ (2002) Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. Clin Geriatr Med 18, 737-757.

29. Gascoin-Lachambre G, Trivin C, Brauner R & Souberbielle JC (2007) Serum procollagen type 1 amino-terminal propeptide (P1NP) as an early predictor of the growth response to growth hormone treatment: Comparison of intrauterine growth retardation and idiopathic short stature. Growth Horm IGF Res 7, 194-200.

30. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD & Napoli JL (1993) Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. Clin Chem 39, 529-533.

31. Zochling J, Chen JS, Seibel M, Schwarz J, Cameron ID, Cumming RG, March L & Sambrook PN (2005) Calcium metabolism in the frail elderly. Clin Rheumatol 24, 576-582.

32. Pauly L, Stehle P & Volkert D (2007) Nutritional situation of elderly nursing home residents. Z Gerontol Geriatr 40, 3-12.

33. Abellan van Kan G, Gambassi G, de Groot LC et al. (2008) Nutrition and aging. The Carla Workshop. J Nutr Health Aging 12, 355-364.

34. Lengyel CO, Whiting SJ & Zello GA (2008) Nutrient inadequacies among elderly residents of long-term care facilities. Can J Diet Pract Res 69, 82-88.

35. Bruyere O, Decock C, Delhez M, Collette J & Reginster JY (2009) Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study. Womens Health (Lond Engl) 5, 49-54.

36. Rapp K, Becker C, Lamb SE, Icks A & Klenk J (2008) Hip fractures in institutionalized elderly people: incidence rates and excess mortality. J Bone Miner Res 23, 1825-1831.

37. Guilley E, Chevalley T, Herrmann F, Baccino D, Hoffmeyer P, Rapin CH & Rizzoli R (2008) Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporos Int 19, 1741-1747.

38. Nakamura K, Oyama M, Takahashi S, Yoshizawa Y, Kobayashi R, Oshiki R, Saito T & Tsuchiya Y (2009) Fracture incidence in nursing homes in Japan. Osteoporos Int.

39. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F & Oden A (2008) Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 19, 1395-1408.

40. Garnero P, Hausherr E, Chapuy MC et al. (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11, 1531-1538.

41. Garnero P, Sornay-Rendu E, Duboeuf F & Delmas PD (1999) Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 14, 1614-1621.

42. Chapurlat RD, Garnero P, Breart G, Meunier PJ & Delmas PD (2000) Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 27, 283-286.

43. Bruyere O, Collette J, Delmas P, Rouillon A, Roux C, Seidel L, Richy F & Reginster JY (2003) Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44, 259-265.

44. Ravn P, Thompson DE, Ross PD & Christiansen C (2003) Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 33, 150-158.

45. Hannon RA & Eastell R (2003) Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 9, 10-15.

46. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK & Delmas PD (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19, 1250-1258.

47. Greenspan SL, Resnick NM & Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90, 2762-2767.

48. Cremers S & Garnero P (2006) Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 66, 2031-2058.

49. Wang J, Lee J, Burns D, Doherty D, Brunner L, Peterson M & DeSilva B (2009) "Fit-for-purpose" method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studies. Aaps J 11, 385-394.

50. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M & Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337, 1641-1647.

51. Lindsay R, Gallagher JC, Kleerekoper M & Pickar JH (2002) Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. Jama 287, 2668-2676.

52. Meunier PJ, Roux C, Seeman E et al. (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350, 459-468.

53. Grados F, Brazier M, Kamel S, Mathieu M, Hurtebize N, Maamer M, Garabedian M, Sebert JL & Fardellone P (2003) Prediction of bone mass density variation by bone remodeling markers in postmenopausal women with vitamin D insufficiency treated with calcium and vitamin D supplementation. J Clin Endocrinol Metab 88, 5175-5179.

54. Asp NG & Contor L (2003) Process for Assessment of Scientific Support for Claims on Food (PASSCLAIM): overall introduction. Eur J Nutr 42 Suppl 1, I3-5.

55. Prentice A, Bonjour JP, Branca F, Cooper C, Flynn A, Garabedian M, Muller D, Pannemans D & Weber P (2003) PASSCLAIM - Bone health and osteoporosis. Eur J Nutr 42 Suppl 1, I28-I49.

56. Chevalley T, Hoffmeyer P, Bonjour JP & Rizzoli R (2010) Early serum IGF-I response to oral protein supplements in elderly women with a recent hip fracture. Clin Nutr 29, 78-83.

57. Chevalley T, Rizzoli R, Manen D, Caverzasio J & Bonjour JP (1998) Arginine increases insulin-like growth factor-I production and collagen synthesis in osteoblast-like cells. Bone 23, 103-109.

58. Dillon EL, Sheffield-Moore M, Paddon-Jones D, Gilkison C, Sanford AP, Casperson SL, Jiang J, Chinkes DL & Urban RJ (2009) Amino acid supplementation increases lean body mass, basal muscle protein synthesis, and insulin-like growth factor-I expression in older women. J Clin Endocrinol Metab 94, 1630-1637.

59. Martin AD (2001) Apports nutritionnels conseillés pour la population française, 3ème édition ed: TEC&DOC, Paris.